Treatment with TUG891, a free fatty acid receptor 4 agonist, restores adipose tissue metabolic dysfunction following chronic sleep fragmentation in mice

International Journal of Obesity

Volumn 40, Issue 7, 2016, Pages 1143-1149

  Gozal, D ^a   Qiao, Z ^a   Almendros, I ^a   Zheng, J ^a   Khalyfa, A ^a   Shimpukade, B ^b   Ulven, T ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; HUMAN INSULIN; PROTEIN INHIBITOR; PROTEIN KINASE B; TUG891; UNCLASSIFIED DRUG; 3-(4-((4-FLUORO-4'-METHYL-(1,1'-BIPHENYL)-2-YL)METHOXY)PHENYL)PROPANOIC ACID; BIPHENYL DERIVATIVE; G PROTEIN COUPLED RECEPTOR; INSULIN; O3FAR1 PROTEIN, MOUSE; PHENYLPROPIONIC ACID DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL POLARITY; CONTROLLED STUDY; DIET RESTRICTION; DRUG ACTIVITY; FLOW CYTOMETRY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAABDOMINAL FAT; MACROPHAGE; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SLEEP; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP FRAGMENTATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VOLUME; WEIGHT GAIN; AGONISTS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; METABOLISM; OBESITY; PATHOPHYSIOLOGY; SLEEP DEPRIVATION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE; ADIPOSE TISSUE, WHITE; ANIMALS; BIPHENYL COMPOUNDS; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, INBRED C57BL; OBESITY; PHENYLPROPIONATES; RECEPTORS, G-PROTEIN-COUPLED; SLEEP DEPRIVATION;

EID: 84973162103     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.37     Document Type: Article

References (48)

1. Gotoh C, Hong YH, Iga T, Hishikawa D, Suzuki Y, Song SH, et al. The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun 2007; 354: 591-597
2. Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 2011; 32: 543-550
3. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell 2010; 142: 687-698
4. Hara T, Kimura I, Inoue D, Ichimura A, Hirasawa A. Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol 2013; 164: 77-116
5. Ulven T, Christiansen E. Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu Rev Nutr 2015; 35: 239-263
6. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. Discovery of a potent and selective GPR120 agonist. J Med Chem 2012; 55: 4511-4515
7. Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol (Lausanne) 2014; 5: 137
8. Milligan G, Ulven T, Murdoch H, Hudson BD. G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. Br J Nutr 2014; 111 (Suppl 1): S3-S7
9. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. GPR120 agonism as a countermeasure against metabolic diseases. Drug Discov Today 2014; 19: 670-679
10. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013; 62: 569-576
11. Heatley EM, Harris M, Battersby M, McEvoy RD, Chai-Coetzer CL, Antic NA. Obstructive sleep apnoea in adults: a common chronic condition in need of a comprehensive chronic condition management approach. Sleep Med Rev 2013; 17: 349-355
12. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, et al. American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2012; 130: e714-e755
13. Spruyt K, Sans Capdevila O, Serpero LD, Kheirandish-Gozal L, Gozal D. Dietary and physical activity patterns in children with obstructive sleep apnea. J Pediatr 2010; 156: 724-730, 730.e1-730.e3
14. Ong CW, O'Driscoll DM, Truby H, Naughton MT, Hamilton GS. The reciprocal interaction between obesity and obstructive sleep apnoea. Sleep Med Rev 2013; 17: 123-131
15. Smith SS, Waight C, Doyle G, Rossa KR, Sullivan KA. Liking for high fat foods in patients with obstructive sleep apnoea. Appetite 2014; 78: 185-192
16. Hakim F, Kheirandish-Gozal L, Gozal D. Obesity and altered sleep: a pathway to metabolic derangements in children?. Semin Pediatr Neurol 2015; 22: 77-85
17. Koren D, O'Sullivan KL, Mokhlesi B. Metabolic and glycemic sequelae of sleep disturbances in children and adults. Curr Diab Rep 2015; 15: 562
18. Gozal D, Kheirandish-Gozal L, Carreras A, Khalyfa A, Peris E. Obstructive sleep apnea and obesity are associated with reduced GPR 120 plasma levels in children. Sleep 2014; 37: 935-941
19. Hakim F, Wang Y, Carreras A, Hirotsu C, Zhang J, Peris E, et al. Chronic sleep fragmentation during the sleep period induces hypothalamic endoplasmic reticulum stress and PTP1b-mediated leptin resistance in male mice. Sleep 2015; 38: 31-40
20. Khalyfa A, Wang Y, Zhang SX, Qiao Z, Abdelkarim A, Gozal D. Sleep fragmentation in mice induces nicotinamide adenine dinucleotide phosphate oxidase 2-dependent mobilization, proliferation, and differentiation of adipocyte progenitors in visceral white adipose tissue. Sleep 2014; 37: 999-1009
21. Wang Y, Carreras A, Lee S, Hakim F, Zhang SX, Nair D, et al. Chronic sleep fragmentation promotes obesity in young adult mice. Obesity (Silver Spring, MD) 2014; 22: 758-762
22. Zhang SX, Khalyfa A, Wang Y, Carreras A, Hakim F, Neel BA, et al. Sleep fragmentation promotes NADPH oxidase 2-mediated adipose tissue inflammation leading to insulin resistance in mice. Int J Obes (Lond) 2014; 38: 619-624
23. Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol 2013; 84: 710-725
24. Nair D, Zhang SX, Ramesh V, Hakim F, Kaushal N, Wang Y, et al. Sleep fragmentation induces cognitive deficits via nicotinamide adenine dinucleotide phosphate oxidase-dependent pathways in mouse. Am J Resp Crit Care Med 2011; 184: 1305-1312
25. Ramesh V, Nair D, Zhang SX, Hakim F, Kaushal N, Kayali F, et al. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-Alpha pathway. J Neuroinflamm 2012; 9: 91
26. Kaushal N, Ramesh V, Gozal D. TNF-α and temporal changes in sleep architecture in mice exposed to sleep fragmentation. PLoS One 2012; 7: e45610
27. Carreras A, Kayali F, Zhang J, Hirotsu C, Wang Y, Gozal D. Metabolic effects of intermittent hypoxia in mice: steady versus high-frequency applied hypoxia daily during the rest period. Am J Physiol Regul Integr Comp Physiol 2012; 303: R700-R709
28. Sargis RM, Neel BA, Brock CO, Lin Y, Hickey AT, Carlton DA, et al. The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1levels. Biochim Biophys Acta 2012; 1822: 952-960
29. Carreras A, Zhang SX, Peris E, Qiao Z, Wang Y, Almendros I, et al. Effect of resveratrol on visceral white adipose tissue inflammation and insulin sensitivity in a mouse model of sleep apnea. Int J Obes (Lond) 2015; 39: 418-423
30. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-94
31. Tanaka T, Katsuma S, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G. Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 523-527
32. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013; 38: 1154-1163
33. Ulven T, Christiansen E. Dietary fatty acids and their potential for controlling etabolic diseases through activation of FFA4/GPR120. Annu Rev Nutr 2015; 35: 239-263
34. Oliveira V, Marinho R, Vitorino D, Santos GA, Moraes JC, Dragano N, et al. Diets containing alpha-linolenic (omega 3) or oleic (omega 9) fatty acids rescues obese mice from insulin resistance. Endocrinology 2015; 156: 4033-4046
35. Kim N, Lee JO, Lee HJ, Kim HI, Kim JK, Lee YW, et al. Endogenous ligand for GPR120, docosahexaenoic acid, exerts benign metabolic effects on the skeletal muscles via AMP-Activated protein kinase pathway. J Biol Chem 2015; 290: 20438-20447
36. Christiansen E, Watterson KR, Stocker CJ, Sokol E, Jenkins L, Simon K, et al. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br J Nutr 2015; 113: 1677-1688
37. Duca FA, Swartz TD, Sakar Y, Covasa M. Increased oral detection, but decreased intestinal signaling for fats in mice lacking gut microbiota. PLoS One 2012; 7: e39748
38. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, Souza CT, et al. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS One 2012; 7: e30571
39. Ichimura A, Hara T, Hirasawa A. Regulation of energy homeostasis via GPR120. Front Endocrinol (Lausanne) 2014; 5: 111
40. Fam BC, Sgambellone R, Ruan Z, Proietto J, Andrikopoulos S. Contribution of the hypothalamus and gut to weight gain susceptibility and resistance in mice. J Endocrinol 2015; 225: 191-204
41. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, Souza CT, et al. LA. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS One 2012; 7: e30571
42. Overton JM, Williams TD. Behavioral and physiologic responses to caloric restriction in mice. Physiol Behav 2004; 81: 749-754
43. Trayhurn P, Denyer G. Mining microarray datasets in nutrition: expression of the GPR120 (n-3 fatty acid receptor/sensor) gene is down-regulated in human adipocytes by macrophage secretions. J Nutr Sci 2012; 1: e3
44. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
45. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-2313
46. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. The 'Big Bang' in obese fat: events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45: 2446-2456
47. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring, MD) 2015; 23: 512-518
48. Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab 2014; 20: 614-625